Showing results (461-470 of 558) with videos related to
Sort By:
Pageof 56
The Lancet. Oncology|December 15, 2023
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 studyEnrique Grande, José Á Arranz, Maria De Santis, et al.European Journal of Cancer (Oxford, England : 1990)|April 8, 2014
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus PanelJohn M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 TrialDaniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.The Lancet. Oncology|December 15, 2023
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 studyAristotelis Bamias, Ian D Davis, Matthew D Galsky, et al.Nature Immunology|November 19, 2020
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19Enrico Brunetta, Marco Folci, Barbara Bottazzi, et al.Rheumatology (Oxford, England)|January 8, 2025
Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohortEliane Roth, Cosimo Bruni, Liubov Petelytska, et al.Cancer Immunology Research|January 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial CancerMatthew D Galsky, Mark Kockx, Juliette Roels, et al.Immunotherapy|November 11, 2020
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findingsHorst-Dieter Hummel, Peter Kufer, Carsten Grüllich, et al.The Lancet. Oncology|May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.The Lancet. Oncology|March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trialThomas Powles, Toni K Choueiri, Laurence Albiges, et al.Pageof 56